Promising biomarkers for systemic lupus erythematosus

Bibliography

• Suh CH, Kim HA. Cytokines and their receptors as biomarkers of systemic lupus erythematosus. Expert Rev Mol Diagn 2008;8:189-98
   PubMed Web of Science ®Google Scholar
• Illei GG, Tackey E, Lapteva L, et al. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004;50:1709-20
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86
   PubMed Web of Science ®Google Scholar
• Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002;47:434-44
   PubMed Web of Science ®Google Scholar
• Manzi S, Navratil JS, Ruffing MJ, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004;50:3596-604
   PubMed Web of Science ®Google Scholar
• Navratil JS, Manzi S, Kao AH, et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 2006;54:670-4
   PubMed Web of Science ®Google Scholar
• Liu CC, Kao AH, Hawkins DM, et al. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci 2009;2:300-8
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Chatham WW, Massarotti EM, et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum 2012;64:4040-7
   PubMed Web of Science ®Google Scholar
• Kim HA, Jeon JY, Choi GS, et al. The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. Clin Immunol 2008;128:277-83
   PubMed Web of Science ®Google Scholar
• Schett G, Smole J, Zimmermann C, et al. The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 2002;11:704-15
   PubMed Web of Science ®Google Scholar
• Gomez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun Rev 2008;7:606-11
   PubMed Web of Science ®Google Scholar
• Bizzaro N, Villalta D, Giavarina D, et al. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev 2012;12:97-106
   PubMed Web of Science ®Google Scholar
• Amarilyo G, La Cava A. miRNA in systemic lupus erythematosus. Clin Immunol 2012;144:26-31
   PubMed Web of Science ®Google Scholar
• Shen N, Liang D, Tang Y, et al. MicroRNAs–novel regulators of systemic lupus erythematosus pathogenesis. Nat Rev Rheumatol 2012;8:701-9
   PubMed Web of Science ®Google Scholar
• Dai Y, Huang YS, Tang M, et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007;16:939-46
   PubMed Web of Science ®Google Scholar
• Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009;60:1065-75
   PubMed Web of Science ®Google Scholar
• Stagakis E, Bertsias G, Verginis P, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis 2011;70:1496-506
   PubMed Web of Science ®Google Scholar
• Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S37-46
   PubMedGoogle Scholar
• Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51
   PubMed Web of Science ®Google Scholar
• Luijten KM, Tekstra J, Bijlsma JW, et al. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012;11:326-9
   PubMed Web of Science ®Google Scholar
• Sturfelt G, Truedsson L. Complement and its breakdown products in SLE. Rheumatology (Oxford) 2005;44:1227-32
   PubMed Web of Science ®Google Scholar
• Kao AH, Navratil JS, Ruffing MJ, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 2010;62:837-44
   PubMed Web of Science ®Google Scholar
• Yang DH, Chang DM, Lai JH, et al. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:1083-7
   PubMed Web of Science ®Google Scholar
• Liu CC, Manzi S, Kao AH, et al. Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside. Rheum Dis Clin North Am 2010;36:161-72; x
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Ward MM. Validation of new biomarkers in systemic autoimmune diseases. Nat Rev Rheumatol 2011;7:708-17
   PubMed Web of Science ®Google Scholar
• Dall'era MC, Cardarelli PM, Preston BT, et al. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692-7
   PubMed Web of Science ®Google Scholar
• Pascual V, Chaussabel D, Banchereau J. A genomic approach to human autoimmune diseases. Annu Rev Immunol 2010;28:535-71
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-15
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-503
   PubMed Web of Science ®Google Scholar
• Herbst R, Liu Z, Jallal B, et al. Biomarkers for systemic lupus erythematosus. Int J Rheum Dis 2012;15:433-44
   PubMed Web of Science ®Google Scholar
• Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009;68:1440-6
   PubMed Web of Science ®Google Scholar
• Lit LC, Wong CK, Tam LS, et al. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006;65:209-15
   PubMed Web of Science ®Google Scholar
• Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006;3:e491
   PubMed Web of Science ®Google Scholar
• Bauer JW, Petri M, Batliwalla FM, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009;60:3098-107
   PubMed Web of Science ®Google Scholar
• Rose T, Grutzkau A, Hirseland H, et al. IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 2012;72(10):1639-45
   PubMed Web of Science ®Google Scholar
• Chun HY, Chung JW, Kim HA, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007;27:461-6
   PubMed Web of Science ®Google Scholar
• Aringer M, Feierl E, Steiner G, et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002;11:102-8
   PubMed Web of Science ®Google Scholar
• Mahmoud RA, El-Gendi HI, Ahmed HH. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin Biochem 2005;38:134-41
   PubMed Web of Science ®Google Scholar
• Dörner T, Lipsky PE. Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus. Lupus 2004;13:283-9
   PubMed Web of Science ®Google Scholar
• Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-42
   PubMed Web of Science ®Google Scholar
• Jacobi AM, Mei H, Hoyer BF, et al. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis 2010;69:305-8
   PubMed Web of Science ®Google Scholar
• Boekel ET, Prins M, Vrielink GJ, et al. Longitudinal studies of the association between peripheral CD27++ plasma cells and systemic lupus erythematosus disease activity: preliminary results. Ann Rheum Dis 2011;70:1341-2
   PubMed Web of Science ®Google Scholar
• Ten Boekel E, Siegert CE, Vrielink GJ, et al. Analyses of CD27++ plasma cells in peripheral blood from patients with bacterial infections and patients with serum antinuclear antibodies. J Clin Immunol 2007;27:467-76
   PubMed Web of Science ®Google Scholar
• Yang DH, Chang DM, Lai JH, et al. Significantly higher percentage of circulating CD27(high) plasma cells in systemic lupus erythematosus patients with infection than with disease flare-up. Yonsei Med J 2010;51:924-31
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-86
   PubMed Web of Science ®Google Scholar
• Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006;15:570-6
   PubMed Web of Science ®Google Scholar
• Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9
   PubMed Web of Science ®Google Scholar
• Ritterhouse LL, Crowe SR, Niewold TB, et al. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum 2011;63:3931-41
   PubMed Web of Science ®Google Scholar
• Zhao LD, Li Y, Smith MF Jr, et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 2010;19:1534-49
   PubMed Web of Science ®Google Scholar
• Duzgun N, Sahin M, Genc Y, et al. Antinucleosome antibodies and systemic lupus erythematosus. Ann NY Acad Sci 2007;1109:421-8
   PubMed Web of Science ®Google Scholar
• Ng KP, Manson JJ, Rahman A, et al. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006;55:900-4
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, Leung HW, et al. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. Transl Res 2010;156:320-5
   PubMed Web of Science ®Google Scholar
• Kim HA, Jeon JY, An JM, et al. C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol 2012;39:728-34
   PubMed Web of Science ®Google Scholar
• Suh CH, Jeong YS, Park HC, et al. Risk factors for infection and role of C-reactive protein in Korean patients with systemic lupus erythematosus. Clin Exp Rheumatol 2001;19:191-4
   PubMed Web of Science ®Google Scholar
• Suh CH, Chun HY, Ye YM, et al. Unresponsiveness of C-reactive protein in the non-infectious inflammation of systemic lupus erythematosus is associated with interleukin 6. Clin Immunol 2006;119:291-6
   PubMed Web of Science ®Google Scholar
• Kim HA, Chun HY, Kim SH, et al. C-reactive protein gene polymorphisms in disease susceptibility and clinical manifestations of Korean systemic lupus erythematosus. J Rheumatol 2009;36:2238-43
   PubMed Web of Science ®Google Scholar
• Mok CC, Birmingham DJ, Ho LY, et al. High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013;65:441-7
   PubMed Web of Science ®Google Scholar
• Sjowall C, Bengtsson AA, Sturfelt G, et al. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004;6:R87-94
   PubMed Web of Science ®Google Scholar
• Tan Y, Yu F, Yang H, et al. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum Immunol 2008;69:840-4
   PubMed Web of Science ®Google Scholar
• O'Neill SG, Giles I, Lambrianides A, et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:845-54
   PubMed Web of Science ®Google Scholar
• Suh CH, Hilliard B, Li S, et al. TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R146
   PubMed Web of Science ®Google Scholar
• Ekman C, Jonsen A, Sturfelt G, et al. Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2011;50:1064-9
   PubMed Web of Science ®Google Scholar
• Kim HA, Nam JY, Jeon JY, et al. Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus. J Clin Immunol 2013;33:143-50
   PubMed Web of Science ®Google Scholar
• Wu J, Ekman C, Jonsen A, et al. Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis. Arthritis Res Ther 2011;13:R62
   PubMed Web of Science ®Google Scholar
• Recarte-Pelz P, Tassies D, Espinosa G, et al. Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. Arthritis Res Ther 2013;15:R41
   PubMed Web of Science ®Google Scholar
• Borchers AT, Leibushor N, Naguwa SM, et al. Lupus nephritis: a critical review. Autoimmun Rev 2012;12:174-94
   PubMed Web of Science ®Google Scholar
• Marto N, Bertolaccini ML, Calabuig E, et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005;64:444-8
   PubMed Web of Science ®Google Scholar
• Grootscholten C, Dieker JW, McGrath FD, et al. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann Rheum Dis 2007;66:693-6
   PubMed Web of Science ®Google Scholar
• Moroni G, Radice A, Giammarresi G, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 2009;68:234-7
   PubMed Web of Science ®Google Scholar
• Cai X, Yang X, Lian F, et al. Correlation between serum anti-C1q antibody levels and renal pathological characteristics and prognostic significance of anti-C1q antibody in lupus nephritis. J Rheumatol 2010;37:759-65
   PubMed Web of Science ®Google Scholar
• Yin Y, Wu X, Shan G, et al. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus 2012;21:1088-97
   PubMed Web of Science ®Google Scholar
• Manson JJ, Ma A, Rogers P, et al. Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther 2009;11:R154
   PubMed Web of Science ®Google Scholar
• Hung WT, Chen YM, Lan JL, et al. Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis. Lupus 2011;20:1404-10
   PubMed Web of Science ®Google Scholar
• Gao HX, Campbell SR, Burkly LC, et al. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 2009;46:24-35
   PubMed Web of Science ®Google Scholar
• Schwartz N, Rubinstein T, Burkly LC, et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009;11:R143
   PubMed Web of Science ®Google Scholar
• Schwartz N, Su L, Burkly LC, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006;27:242-50
   PubMed Web of Science ®Google Scholar
• El-Shehaby A, Darweesh H, El-Khatib M, et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 2011;31:848-56
   PubMed Web of Science ®Google Scholar
• Rovin BH, Song H, Birmingham DJ, et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005;16:467-73
   PubMed Web of Science ®Google Scholar
• Barbado J, Martin D, Vega L, et al. MCP-1 in urine as biomarker of disease activity in Systemic Lupus Erythematosus. Cytokine 2012;60:583-6
   PubMed Web of Science ®Google Scholar
• Zhang X, Nagaraja HN, Nadasdy T, et al. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int 2012;81:401-6
   PubMed Web of Science ®Google Scholar
• Pawar RD, Pitashny M, Gindea S, et al. Neutrophil gelatinase-associated lipocalin is instrumental in the pathogenesis of antibody-mediated nephritis in mice. Arthritis Rheum 2012;64:1620-31
   PubMed Web of Science ®Google Scholar
• Hinze CH, Suzuki M, Klein-Gitelman M, et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 2009;60:2772-81
   PubMed Web of Science ®Google Scholar
• Pitashny M, Schwartz N, Qing X, et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 2007;56:1894-903
   PubMed Web of Science ®Google Scholar
• Suzuki M, Wiers KM, Klein-Gitelman MS, et al. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol 2008;23:403-12
   PubMed Web of Science ®Google Scholar
• Rubinstein T, Pitashny M, Levine B, et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 2010;49:960-71
   PubMed Web of Science ®Google Scholar
• Kiani AN, Wu T, Fang H, et al. Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. J Rheumatol 2012;39:1231-7
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010;6:358-67
   PubMed Web of Science ®Google Scholar
• Hanly JG, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011;70:1726-32
   PubMed Web of Science ®Google Scholar
• Morris RG, Anderson E, Lynch GS, et al. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 1986;319:774-6
   PubMed Web of Science ®Google Scholar
• Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008;58:1130-5
   PubMed Web of Science ®Google Scholar
• Yoshio T, Onda K, Nara H, et al. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2006;54:675-8
   PubMed Web of Science ®Google Scholar
• Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005;12:392-8
   PubMed Web of Science ®Google Scholar
• Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006;33:1553-8
   PubMed Web of Science ®Google Scholar
• Gerli R, Caponi L. Anti-ribosomal P protein antibodies. Autoimmunity 2005;38:85-92
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod Rheumatol 2009;19:457-68
   PubMed Web of Science ®Google Scholar
• Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006;54:312-24
   PubMed Web of Science ®Google Scholar
• Liu CC, Kao AH, Manzi S, et al. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis 2013;5:210-33
   PubMedGoogle Scholar